You just read:

EntreMed's ENMD-2076 Phase 1 Results Demonstrating Activity in Refractory Cancer Patients Accepted For Publication in Clinical Cancer Research

News provided by

EntreMed, Inc.

Feb 04, 2011, 07:00 ET